

(19)  Canadian  
Intellectual Property  
Office

An Agency of  
Industry Canada

Office de la Propriété  
Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

(11) **CA 2 360 360** (13) **A1**

(40) 20.07.2000  
(43) 20.07.2000

(12)

(21) 2 360 360

(22) 06.01.2000

(51) Int. Cl. 7: **C07D 211/58, C07C 275/00,  
C07D 295/18, C07D 295/20,  
C07D 295/22, A61P 25/28,  
A61K 31/445, A61K 31/496,  
C07D 213/75, C07D 211/96**

(85) 06.07.2001

(86) PCT/JP00/00017

(87) WO00/42011

(30) PP 8180 AU 14.01.1999

(71) FUJISAWA PHARMACEUTICAL CO., LTD.,  
4-7, Doshomachi 3-chome  
Chuo-ku, Osaka-shi  
541-8514, OSAKA, XX (JP).


(72) AOKI, SATOSHI (JP).  
YAMADA, AKIRA (JP).

(74) SWABEY OGILVY RENAULT

(54) COMPOSES AMIDE  
(54) AMIDE COMPOUNDS

(57)

<sup>222</sup>This invention relates to new amide compounds having the potentiation of the <sup>2</sup>cholinergic activity, etc., and represented by general formula (I), wherein R1 <sup>2</sup>is acyl, R2 is lower alkyl, etc., A is a single bond, (1) or -SO2-, E is lower <sup>2</sup>alkylene, etc., X is CH or N, Y is a single bond, etc., Q is -CH2-, etc., and <sup>2</sup>R3 and R4 are taken together to form lower alkylene, etc., and <sup>2</sup>pharmaceutically acceptable salts thereof, to processes for preparation <sup>2</sup>thereof and a pharmaceutical composition comprising the same.<sup>2</sup>





Office de la Propriété  
Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2360360 A1 2000/07/20

(21) **2 360 360**


(12) **DEMANDE DE BREVET CANADIEN  
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2000/01/06  
(87) Date publication PCT/PCT Publication Date: 2000/07/20  
(85) Entrée phase nationale/National Entry: 2001/07/06  
(86) N° demande PCT/PCT Application No.: JP 00/00017  
(87) N° publication PCT/PCT Publication No.: WO 00/42011  
(30) Priorité/Priority: 1999/01/14 (PP 8180) AU

(51) Cl.Int.<sup>7</sup>/Int.Cl.<sup>7</sup> C07D 211/58, A61K 31/496,  
A61K 31/445, A61P 25/28, C07D 295/22, C07D 211/96,  
C07D 213/75, C07C 275/00, C07D 295/20, C07D 295/18  
(71) Demandeur/Applicant:  
FUJISAWA PHARMACEUTICAL CO., LTD., JP  
(72) Inventeurs/Inventors:  
AOKI, SATOSHI, JP;  
YAMADA, AKIRA, JP  
(74) Agent: SWABEY OGILVY RENAULT

(54) Titre : COMPOSES AMIDE  
(54) Title: AMIDE COMPOUNDS



(57) Abrégé/Abstract:

This invention relates to new amide compounds having the potentiation of the cholinergic activity, etc., and represented by general formula (I), wherein R<sup>1</sup> is acyl, R<sup>2</sup> is lower alkyl, etc., A is a single bond, (1) or -SO<sub>2</sub>-, E is lower alkylene, etc., X is CH or N, Y is a single bond, etc., Q is -CH<sub>2</sub>-, etc., and R<sup>3</sup> and R<sup>4</sup> are taken together to form lower alkylene, etc., and pharmaceutically acceptable salts thereof, to processes for preparation thereof and a pharmaceutical composition comprising the same.

Canada

<http://opic.gc.ca> · Ottawa-Hull K1A 0C9 · <http://cipo.gc.ca>

OPIC · CIPO 191

OPIC



CIPO

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C07D 211/58, 213/75, 211/96, 295/20, 295/18, 295/22, A61K 31/445, 31/496, A61P 25/28</b>	<b>A1</b>	(11) International Publication Number: <b>WO 00/42011</b> (43) International Publication Date: 20 July 2000 (20.07.00)
--	-----------	---

(21) International Application Number: **PCT/JP00/00017**  
(22) International Filing Date: 6 January 2000 (06.01.00)

(30) Priority Data:  
PP 8180 14 January 1999 (14.01.99) AU

(71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): YAMADA, Akira [JP/JP]; 4-8-30, Sawada, Fujiidera-shi, Osaka 583-0011 (JP). AOKI, Satoshi [JP/JP]; 2-38-3, Maborikaigan, Yokosuka-shi, Kanagawa 239-0801 (JP).


(74) Agent: TABUSHI, Eiji; Fujisawa Pharmaceutical Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8514 (JP).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: AMIDE COMPOUNDS



## (57) Abstract

This invention relates to new amide compounds having the potentiation of the cholinergic activity, etc., and represented by general formula (I), wherein R<sup>1</sup> is acyl, R<sup>2</sup> is lower alkyl, etc., A is a single bond, (1) or -SO<sub>2</sub>-, E is lower alkylene, etc., X is CH or N, Y is a single bond, etc., Q is -CH<sub>2</sub>-, etc., and R<sup>3</sup> and R<sup>4</sup> are taken together to form lower alkylene, etc., and pharmaceutically acceptable salts thereof, to processes for preparation thereof and a pharmaceutical composition comprising the same.

## DESCRIPTION

## AMIDE COMPOUNDS

## 5 TECHNICAL FIELD

This invention relates to new amide compounds and pharmaceutically acceptable salts thereof which are useful as a medicament.

## 10 BACKGROUND ART

Some aminopiperazine derivatives have been known as useful anti-amnesia or anti-dementia agents, for example, in PCT International Publication Nos. WO 91/01979 and WO 98/35951.

15

## DISCLOSURE OF INVENTION

This invention relates to new amide compounds and pharmaceutically acceptable salts thereof.

More particularly, it relates to new amide compounds and pharmaceutically acceptable salts thereof which have the potentiation of the cholinergic activity, to processes for the preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the treatment and/or prevention of disorders in the central nervous system for mammals, and more particularly to method for the treatment and/or prevention of amnesia, dementia (e.g., senile dementia, Alzheimer's dementia, dementia associated with various diseases such as cerebral vascular dementia, cerebral post-traumatic dementia, dementia due to brain tumor, dementia due to chronic subdural hematoma, dementia due to normal pressure hydrocephalus, post-meningitis dementia, Parkinson's disease type dementia, etc.), and the like. Additionally, the object compound is expected to be useful as therapeutical and/or preventive agents for schizophrenia, depression, stroke, head injury, nicotine withdrawal, spinal cord injury, anxiety,

35

pollakiuria, incontinence of urine, myotonic dystrophy, attention deficit hyperactivity disorder, excessive daytime sleepiness (narcolepsy), Parkinson's disease or autism.


One object of this invention is to provide new and  
5 useful amide compounds and pharmaceutically acceptable salts thereof which possess the potentiation of the cholinergic activity.

Another object of this invention is to provide processes for preparation of said amide compounds and salts thereof.

10 A further object of this invention is to provide a pharmaceutical composition comprising, as an active ingredient, said amide compounds and pharmaceutically acceptable salt thereof.

Still further object of this invention is to provide a  
15 therapeutic method for the treatment and/or prevention of aforesaid diseases in mammals, using said amide compounds and pharmaceutically acceptable salts thereof.

The amide compounds of this invention are new and can be  
20 represented by the following general formula [I]:



25

wherein  $\text{R}^1$  is acyl,

$\text{R}^2$  is lower alkyl, lower alkoxy, lower alkylamino, lower alkenyl, lower alkenyloxy, lower alkenylamino, lower alkynyl, lower alkynyloxy, lower alkynylamino,  
30 cyclo(lower)alkyl, cyclo(lower)alkyloxy, cyclo(lower)alkylamino, aryl, aryloxy, arylamino, a heterocyclic group or amino substituted with a heterocyclic group, each of which may be substituted with suitable substituent(s); or acyl;  
35

A is a single bond,  $\overset{\text{O}}{\parallel}\text{C}-$  or  $-\text{SO}_2-$ ,

E is lower alkylene optionally substituted with suitable substituent(s),

5 X is CH or N,

Y is a single bond, lower alkylene or  $\overset{\text{R}^5}{\underset{|}{\text{N}}}-$   
(wherein  $\text{R}^5$  is hydrogen, lower alkyl,  
substituted-lower alkyl, an N-protective group,  
aryl, acyl or a heterocyclic group),

10 Q is  $-\text{CH}_2-$ ,  $\overset{\text{O}}{\parallel}\text{C}-$ ,  $-\text{SO}_2-$  or  $-\text{N}=\text{CH}-$ , and

$\text{R}^3$  and  $\text{R}^4$  are each hydrogen or lower alkyl, or are  
taken together to form lower alkylene optionally  
condensed with a cyclic hydrocarbon or a  
heterocyclic ring,

15 provided that when X is N,

then 1) Y is a single bond, and


20 Q is  $-\text{CH}_2-$ ,  $\overset{\text{O}}{\parallel}\text{C}-$  or  $-\text{SO}_2-$ , or

2) Y is lower alkylene,  
and pharmaceutically acceptable salts thereof.


The object compound [I] or its salt can be prepared by  
processes as illustrated in the following reaction schemes.

25

#### Process 1



+



30

[II]


or its salt

[III]

or its reactive derivative  
at the carboxy or sulfo  
group, or a salt thereof

35


4



[Ia]


or its salt

5

Process 2


10

15

Process 3

20

25







[Ic]

or its salt

30

35

Process 410 Process 5Process 6




5

[Ie]  
or its salt

Process 7

10




15

[X]  
or its salt

[If]  
or its salt

Process 8

20




[If]  
or its salt

[Ig]  
or its salt

25

Process 9

30



[Ih]  
or its salt

[Ii]  
or its salt

35



$R_b^5$  is lower alkyl,  
 $Z_b$  is an acid residue,  
 $Z_c$  is an acid residue, and  
 $Y_a$  is lower alkylene.

5

In the above and subsequent description of the present specification, suitable examples of the various definitions to be included within the scope of the invention are explained in detail in the following.

10

The term "lower" is intended to mean a group having 1 to 6 carbon atom(s), unless otherwise provided.

The lower moiety in the term "lower alkenyl", "lower alkenyloxy", "lower alkenylamino", "lower alkynyl", "lower alkynyloxy" and "lower alkynylamino" is intended to mean a group having 2 to 6 carbon atoms.

The lower moiety in the terms "cyclo(lower)alkyl", "cyclo(lower)alkyloxy" and "cyclo(lower)alkylamino" is intended to mean a group having 3 to 6 carbon atoms.

Suitable "lower alkyl" and lower alkyl moiety in the terms "substituted-lower alkyl", "ar(lower)alkyl", "halo(lower)alkyl", "lower alkylamino", "lower alkylsilyl", "lower alkylthio" and "lower alkylsulfonyl" may be a straight or branched  $C_1$ - $C_6$  alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, ethylpropyl, hexyl or the like, in which preferable one is methyl.

Suitable "lower alkenyl" and lower alkenyl moiety in the terms "lower alkenyloxy" and "lower alkenylamino" may be a straight or branched  $C_2$ - $C_6$  alkenyl such as ethenyl, propenyl, butenyl, pentenyl, hexenyl, isopropenyl, butadienyl, pentadienyl, hexadienyl or the like, in which preferable one is ethenyl, propenyl or butadienyl.

Suitable "lower alkynyl" and lower alkynyl moiety in the terms "lower alkynyloxy" and "lower alkynylamino" may be a straight or branched  $C_2$ - $C_6$  alkynyl such as ethynyl, propargyl,

butynyl or the like, in which preferable one is ethynyl.

Suitable "cyclo(lower)alkyl" and cyclo(lower)alkyl moiety in the terms "cyclo(lower)alkyloxy" and "cyclo(lower)alkylamino" may be cyclo(C<sub>3</sub>-C<sub>6</sub>)alkyl such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in which preferable one is cyclopropyl.

Suitable "aryl" and aryl or ar moiety in the terms "ar(lower)alkoxy", "aryloxy", "arylamino", "arylsulfonyl", "aroxy" and "ar(lower)alkyl" may be phenyl, naphthyl, phenyl substituted with lower alkyl [e.g. tolyl, xylyl, mesityl, cumenyl, di(tert-butyl)phenyl, etc.] and the like, in which preferable one is phenyl or tolyl.

Suitable "ar(lower)alkyl" may be benzyl, phenethyl, phenylpropyl, benzhydryl, trityl and the like, in which preferable one is benzyl.

Suitable "lower alkylene" and lower alkylene moiety in the term "lower alkylenedioxy" may be a straight or branched C<sub>1</sub>-C<sub>6</sub> alkylene such as methylene, ethylene, trimethylene, propylene, tetramethylene, pentamethylene, hexamethylene, ethylethylene or the like, in which preferable one is methylene, ethylene or trimethylene.

Suitable "lower alkoxy" and lower alkoxy moiety in the terms "ar(lower)alkoxy" and "halo(lower)alkoxy" may be a straight or branched C<sub>1</sub>-C<sub>6</sub> alkoxy such as methoxy, ethoxy, propoxy, isopropoxy, methylpropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, hexyloxy or the like, in which preferable one is methoxy or tert-butoxy.

Suitable "ar(lower)alkoxy" may be benzyloxy, phenethyloxy, phenylpropoxy, benzhydryloxy, trityloxy and the like.

Suitable "halogen" and halo moiety in the term "halo(lower)alkyl" may be fluorine, chlorine, bromine and iodine, in which preferable one is fluorine, chlorine or iodine.

Suitable "halo(lower)alkyl" may be lower alkyl

substituted with one or more halogens such as chloromethyl, dichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, pentachloroethyl or the like, in which preferable one is trifluoromethyl.

5       Suitable "halo(lower)alkoxy" may be lower alkoxy substituted with one or more halogens such as chloromethoxy, dichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, pentachloromethoxy or the like, in which preferable one is trifluoromethoxy.

10       Suitable "lower alkylamino" may be mono or di(lower alkylamino) such as methylamino, ethylamino, propylamino, isopropylamino, butylamino, tert-butylamino, isobutylamino, pentylamino, hexylamino, dimethylamino, diethylamino, dipropylamino, dibutylamino, diisopropylamino, dipentylamino, 15   dihexylamino, N-methylethylamino or the like, in which preferable one is dimethylamino.

      Suitable "lower alkylsilyl" may be mono, di, or tri(lower)alkylsilyl such as trimethylsilyl, dimethylsilyl, triethylsilyl or the like, in which preferable one is 20   trimethylsilyl.

      Suitable "lower alkylenedioxy" may be methylenedioxy, ethylenedioxy and the like, in which preferable one is methylenedioxy.

      Suitable "heterocyclic group" may be one containing at 25   least one hetero atom selected from nitrogen, sulfur and oxygen atom, and may include saturated or unsaturated, monocyclic or polycyclic heterocyclic group, and preferable heterocyclic group may be N-containing heterocyclic group such as unsaturated 3 to 6-membered heteromonocyclic group 30   containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl [e.g. 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.], tetrazolyl [e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.], etc.; 35   saturated 3 to 7-membered heteromonocyclic group containing 1

- to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, homopiperazinyl, etc.];  
unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl,  
5 benzimidazolyl, quinolyl, isoquinolyl, imidazopyridyl, indazolyl, benzotriazolyl, tetrazolo-pyridazinyl [e.g. tetrazolo[1,5-b]pyridazinyl, etc.], quinoxalinyl, etc.;
- unsaturated 3 to 6-membered heteromonocyclic group containing  
10 an oxygen atom, for example, pyranyl, furyl, etc.;
- saturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, 1H-tetrahydropyranyl, tetrahydrofuranlyl, etc.;
- unsaturated 3 to 6-membered heteromonocyclic group containing  
15 1 to 2 sulfur atoms, for example, thienyl, etc.;
- unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl [e.g. 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.], oxazolinyl [e.g.  
20 2-oxazolinyl, etc.], etc.;
- saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl, etc.];
- unsaturated condensed heterocyclic group containing 1 to 2  
25 oxygen atoms and 1 to 3 nitrogen atoms [e.g. benzofurazanyl, benzoxazolyl, benzoxadiazolyl, etc.];
- unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl [e.g. 1,2,4-thiadiazolyl, 1,3,4-  
30 thiadiazolyl, 1,2,5-thiadiazolyl, etc.], etc.;
- saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g. thiazolidinyl, etc.];
- unsaturated condensed heterocyclic group containing 1 to 2  
35 sulfur atoms and 1 to 3 nitrogen atoms [e.g. benzothiazolyl,

benzothiadiazolyl, etc.);

unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms [e.g. benzofuranyl, benzodioxolyl, chromanyl, etc.] and the like.

5 Said "heterocyclic group" may be substituted with lower alkyl as exemplified above, in which preferable one is thienyl, pyridyl, methylpyridyl, quinolyl, indolyl, quinoxalinyl, benzofuranyl or tetramethylchromanyl, and more preferable one is pyridyl.

10 Suitable "acyl" may be carboxy; esterified carboxy; carbamoyl substituted with lower alkyl, aryl, ar(lower)alkyl, arylsulfonyl, lower alkylsulfonyl or a heterocyclic group; substituted or unsubstituted arylsulfonyl; lower alkylsulfonyl; cyclo(lower)alkylcarbonyl;  
15 lower alkanoyl; substituted or unsubstituted aroyl; a heterocycliccarbonyl and the like.

The esterified carboxy may be substituted or unsubstituted lower alkoxy carbonyl [e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, 20 tert-butoxycarbonyl, hexyloxycarbonyl, 2-iodoethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, etc.], substituted or unsubstituted aryloxy carbonyl [e.g. phenoxycarbonyl, 4-nitrophenoxycarbonyl, 2-naphthylloxycarbonyl, etc.], substituted or unsubstituted ar(lower)alkoxy carbonyl [e.g.  
25 benzyloxycarbonyl, phenethylloxycarbonyl, benzhydryloxycarbonyl, 4-nitrobenzyloxycarbonyl, etc.] and the like, in which preferable one is unsubstituted lower alkoxy carbonyl and more preferable one is methoxycarbonyl or tert-butoxycarbonyl.

30 The carbamoyl substituted with lower alkyl may be methylcarbamoyl, ethylcarbamoyl, propylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, N-methyl-N-ethylcarbamoyl and the like.

The carbamoyl substituted with aryl may be  
35 phenylcarbamoyl, naphthylcarbamoyl, lower alkyl-substituted

phenylcarbamoyl [e.g. tolylcarbamoyl, xylylcarbamoyl, etc.] and the like.

The carbamoyl substituted with ar(lower)alkyl may be benzylcarbamoyl, phenethylcarbamoyl, phenylpropylcarbamoyl  
5 and the like, in which preferable one is benzylcarbamoyl.

The carbamoyl substituted with arylsulfonyl may be phenylsulfonylcarbamoyl, tolylsulfonylcarbamoyl and the like.

The carbamoyl substituted with lower alkylsulfonyl may be methylsulfonylcarbamoyl, ethylsulfonylcarbamoyl and the  
10 like.

The carbamoyl substituted with a heterocyclic group may be one substituted with a heterocyclic group as mentioned above.

15 The lower alkanoyl may be formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl and the like, in which preferable one is acetyl or pivaloyl.

The substituted or unsubstituted aroyl may be benzoyl, naphthoyl, toluoyl, di(tert-butyl)benzoyl,  
20 halo(lower)alkoxybenzoyl [e.g. trifluoromethoxybenzoyl, etc.] and the like, in which preferable one is benzoyl or trifluoromethoxybenzoyl.

The substituted or unsubstituted arylsulfonyl may be phenylsulfonyl, tolylsulfonyl, halophenylsulfonyl [e.g.,  
25 fluorophenylsulfonyl, etc.] and the like, in which preferable one is fluorophenylsulfonyl.

The lower alkylsulfonyl may be methylsulfonyl, ethylsulfonyl and the like, in which preferable one is methylsulfonyl.

30 The cyclo(lower)alkylcarbonyl may be cyclo(C<sub>3</sub>-C<sub>6</sub>)-alkylcarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl or cyclohexylcarbonyl, in which preferable one is cyclopropylcarbonyl.

The heterocyclic moiety in the term  
35 "a heterocycliccarbonyl" may be one mentioned above as a

heterocyclic group.

Suitable "acid residue" may be halogen [e.g. fluoro, chloro, bromo, iodo], arenesulfonyloxy [e.g. benzenesulfonyloxy, tosyloxy, etc.], alkanesulfonyloxy [e.g. mesyloxy, ethanesulfonyloxy, etc.], and the like, in which preferable one is halogen.

Suitable "N-protective group" may be common N-protective group such as substituted or unsubstituted lower alkanoyl [e.g. formyl, acetyl, propionyl, trifluoroacetyl, etc.], lower alkoxy carbonyl [e.g. tert-butoxycarbonyl, tert-amylloxycarbonyl, etc.], substituted or unsubstituted aralkyloxycarbonyl [e.g. benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, etc.], 9-fluorenylmethoxycarbonyl, substituted or unsubstituted arenesulfonyl [e.g. benzenesulfonyl, tosyl, etc.], nitrophenylsulfenyl, aralkyl [e.g. trityl, benzyl, etc.] or the like, in which preferable one is lower alkoxy carbonyl and more preferable one is tert-butoxycarbonyl.

Suitable "cyclic hydrocarbon" may be a saturated or unsaturated cyclic hydrocarbon such as cyclopentane, cyclohexane, benzene, naphthalene, indan, indene or the like.

Suitable "substituted-lower alkyl" may be lower alkyl substituted with halogen, aryl, acyl, lower alkoxy, aryloxy and the like, in which preferable one is benzyl.

Suitable "heterocyclic ring" may be one which is a heterocyclic group, as mentioned above, added by hydrogen.

Preferred "acyl" for  $R^1$  may be lower alkanoyl; lower alkoxy carbonyl; aroyl optionally substituted with halo(lower)alkoxy; arylsulfonyl optionally substituted with halogen; lower alkylsulfonyl; or cyclo(lower)alkyl carbonyl, in which more preferable one is acetyl, pivaloyl, methoxycarbonyl, tert-butoxycarbonyl, benzoyl, trifluoromethoxybenzoyl, fluorophenylsulfonyl, methylsulfonyl

or cyclopropylcarbonyl.

Preferred "suitable substituent" as the substituent of lower alkyl, lower alkoxy, lower alkylamino, lower alkenyl, lower alkenyloxy, lower alkenylamino, lower alkynyl, lower alkynyloxy, lower alkynylamino, cyclo(lower)alkyl, cyclo(lower)alkyloxy, cyclo(lower)alkylamine, aryl, aryloxy, arylamino, a heterocyclic group or amino substituted a heterocyclic group for  $R^2$  may be halo(lower)alkyl, halo(lower)alkoxy, lower alkenyl, lower alkynyl, lower alkylamino, acylamino, acyl, lower alkylsilyl, lower alkoxy, aryl, lower alkylenedioxy, acyloxy, hydroxy, nitro, amino, cyano, halogen, aryloxy, lower alkylthio and the like.

Preferred "aryl which may be substituted with suitable substituent(s)" for  $R^2$  may be aryl optionally substituted with halogen, in which more preferable one is fluorophenyl.

Preferred "arylamino which may be substituted with suitable substituent(s)" for  $R^2$  may be arylamino optionally substituted with halogen, in which preferable one is phenylamino or fluorophenylamino.

Preferred "aryloxy which may be substituted with suitable substituent(s)" for  $R^2$  may be aryloxy optionally substituted with halogen, in which preferable one is fluorophenoxy.

Preferred "lower alkylene" for Y may be methylene.

Preferred "lower alkyl" for  $R^5$  in Y may be methyl.

Preferred "N-protective group" for  $R^5$  in Y may be tert-butoxycarbonyl.

Preferred "suitable substituent" as the substituent of lower alkylene for E may be oxo, lower alkyl, hydroxy(lower)alkyl or acyl, in which more preferable one is oxo, dioxo, methyl, dimethyl, hydroxymethyl, or benzylcarbamoyle.

Preferred "lower alkylene" for E may be methylene, ethylene or trimethylene, and more preferable one is ethylene.

Preferred "lower alkyl" for  $R^3$  and  $R^4$  may be methyl.

Preferred "lower alkylene which R<sup>3</sup> and R<sup>4</sup> are taken together to form" may be ethylene or trimethylene.

Preferred "a cyclic hydrocarbon with which lower alkylene is condensed" may be benzene.

5 Preferred compound [I] is one having lower alkanoyl, lower alkoxy carbonyl, aroyl, aroyl substituted with halo(lower)alkoxy, lower alkylsulfonyl, arylsulfonyl, arylsulfonyl substituted with halogen or cyclo(lower)alkylcarbonyl for R<sup>1</sup>, aryl, aryloxy or arylamino, 10 each aryl of which may be substituted with halogen; pyridyl; or pyridylamino for R<sup>2</sup>, a single bond for

A, ethylene for E, CH for X,  $\begin{array}{c} \text{H} \\ | \\ -\text{N}- \end{array}$  for Y,  $\begin{array}{c} \text{O} \\ || \\ -\text{C}- \end{array}$  for Q, and 15 ethylene for R<sup>3</sup> and R<sup>4</sup> to be taken together to form, or lower alkanoyl, lower alkoxy carbonyl, aroyl, aroyl substituted with halo(lower)alkoxy, lower alkylsulfonyl, arylsulfonyl, arylsulfonyl substituted with halogen or cyclo(lower)alkylcarbonyl for R<sup>1</sup>, aryl, aryloxy or arylamino, 20 each aryl of which may be substituted with halogen; pyridyl; or pyridylamino for R<sup>2</sup>, a single bond for

A, ethylene for E, N for X, a single bond for Y,  $\begin{array}{c} \text{O} \\ || \\ -\text{C}- \end{array}$  for Q, and ethylene for R<sup>3</sup> and R<sup>4</sup> to be taken together to form.

Suitable pharmaceutically acceptable salts of the object 25 compound [I] are conventional non-toxic salts and include acid addition salt such as an inorganic acid addition salt [e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.], an organic acid addition salt [e.g. formate, acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, 30 benzenesulfonate, toluenesulfonate, etc.], a salt with an amino acid [e.g. aspartic acid salt, glutamic acid salt, etc.], a metal salt such as an alkali metal salt [e.g. sodium salt, potassium salt, etc.] and alkaline earth metal salt [e.g. calcium salt, magnesium salt, etc.] and the like.

The processes for preparing the object compound [I] are explained in detail in the following.

Process 1

5       The compound [Ia] or its salt can be prepared by reacting a compound [II] or its salt with a compound [III] or its reactive derivative at the carboxy or sulfo group, or a salt thereof.

10       Suitable salts of the compounds [Ia] and [II] may be the same as those exemplified for the compound [I].

      Suitable salts of the compound [III] and its reactive derivative at the carboxy or sulfo group may be metal salt or alkaline earth metal salt as exemplified for the compound [I].

15       Suitable reactive derivative at the carboxy or sulfo group or the compound [III] may include an ester, an acid halide, an acid anhydride and the like. The suitable examples of the reactive derivatives may be an acid halide [e.g. acid chloride, acid bromide, etc.];  
a symmetrical acid anhydride; a mixed acid anhydride with an  
20   acid such as aliphatic carboxylic acid [e.g. acetic acid, pivalic acid, etc.], substituted phosphoric acid [e.g. dialkylphosphoric acid, diphenylphosphoric acid, etc.];  
an ester such as substituted or unsubstituted lower alkyl ester [e.g. methyl ester, ethyl ester, propyl ester, hexyl  
25   ester, trichloromethyl ester, etc.], substituted or unsubstituted ar(lower)alkyl ester [e.g. benzyl ester, benzhydryl ester, p-chlorobenzyl ester, etc.], substituted or unsubstituted aryl ester [e.g. phenyl ester, tolyl ester, 4-nitrophenyl ester, 2,4-dinitrophenyl ester,  
30   pentachlorophenyl ester, naphthyl ester, etc.], or an ester with N,N-dimethylhydroxylamine, N-hydroxysuccinimide, N-hydroxyphthalimide or 1-hydroxybenzotriazole, 1-hydroxy-6-chloro-1H-benzotriazole, or the like. These reactive derivatives can be optionally selected according to the kind  
35   of the compound [III] to be used.

The reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, chloroform, methylene chloride, ethylene dichloride, tetrahydrofuran, acetonitrile, ethyl acetate, N,N-dimethylformamide, pyridine  
5 or any other organic solvent which does not adversely influence the reaction. Among these solvents, hydrophilic solvent may be used in a mixture with water.

The reaction is also preferably carried out in the presence of a conventional base such as triethylamine,  
10 diisopropylethylamine, pyridine, N,N-dimethylaminopyridine, etc., or a mixture thereof.

When the compound [III] is used in a free acid form or its salt form in the reaction, the reaction is preferably carried out in the presence of a conventional condensing  
15 agent such as N,N'-dicyclohexylcarbodiimide, N-cyclohexyl-N'-morpholinoethylcarbodiimide, N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide, thionyl chloride, oxalyl chloride, lower alkoxycarbonyl halide [e.g. ethyl chloroformate, isobutyl chloroformate, etc.],  
20 1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole, or the like.

The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.

## 25 Process 2

The compound [Ib] or its salt can be prepared by reacting a compound [II] or its salt with a compound [IV].

Suitable salts of the compounds [Ib] and [II] may be the same as those exemplified for the compound [I].

30 This reaction is usually carried out in a solvent such as dioxane, tetrahydrofuran, benzene, toluene, chloroform, methylene chloride or any other organic solvent which does not adversely influence the reaction.

The reaction temperature is not critical, and the  
35 reaction is usually carried out under cooling to warming.

Process 3

The compound [Ic] or its salt can be prepared by reacting a compound [V] or its salt with a compound [III] or its reactive derivative at the carboxy or sulfo group, or a salt thereof.

Suitable salts of the compounds [Ic] and [V] may be the same as those exemplified for the compound [I].

Suitable salts of the compound [III] and its reactive derivative at the carboxy or sulfo group may be metal salt or alkaline earth metal salt as exemplified for the compound [I].

This reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction condition [e.g. solvent, reaction temperature, etc.] of this reaction are to be referred to those as explained in Process 1.

Process 4

The compound [Id] or its salt can be prepared by reacting a compound [V] or its salt with a compound [IV].

Suitable salts of the compounds [Id] and [V] may be the same as those exemplified for the compound [I].

This reaction can be carried out in substantially the same manner as Process 2, and therefore the reaction mode and reaction condition [e.g. solvent, reaction temperature, etc.] of this reaction are to be referred to those explained in Process 2.

Process 5

The compound [I] or its salt can be prepared by reacting a compound [VI] or its salt with a compound [VII] or its reactive derivative at the carboxy or sulfo group, or a salt thereof.

Suitable salt of the compound [VI] may be acid addition salt as exemplified for the compound [I].

Suitable salts of the compound [VII] and its reactive derivative at the carboxy or sulfo group may be metal salt or alkaline earth metal salt as exemplified for the compound [I].

5 This reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction condition [e.g. solvent, reaction temperature, etc.] of this reaction are to be referred to those as explained in Process 1.

10 Process 6

The compound [Ie] or its salt can be prepared by reacting a compound [VIII] or its reactive derivative at the carboxy group or sulfo group, or a salt thereof with a compound [IX] or its salt.

15 Suitable salts of the compounds [Ie], [VIII] and its reactive derivative at the carboxy or sulfo group may be the same as those exemplified for the compound [I].

Suitable salt of the compound [IX] may be acid addition salt as exemplified for the compound [I].

20 This reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction condition [e.g. solvent, reaction temperature, etc.] of this reaction are to be referred to those as explained in Process 1.

25

Process 7

The compound [If] can be prepared by reacting a compound [X] or its salt with a compound [XI].

30 Suitable salts of the compounds [If] and [X] may be the same as those exemplified for the compound [I].

The present reaction is preferably carried out in the presence of base such as an alkali metal [e.g. lithium, sodium, potassium, etc.], alkaline earth metal [e.g. calcium, etc.], alkali metal hydride [e.g. sodium hydride, etc.],  
35 alkaline earth metal hydride [e.g. calcium hydride, etc.],

the hydroxide or carbonate or bicarbonate of an alkali metal or an alkaline earth metal [e.g. potassium bicarbonate, etc.] and the like.

5 This reaction is usually carried out in a solvent such as N,N-dimethylformamide, diethyl ether, tetrahydrofuran, dioxane, benzene, toluene, acetonitrile or any other solvent which does not adversely influence the reaction.

The reaction temperature is not critical, and the reaction is usually carried out under cooling to heating.

10

#### Process 8

The object compound [Ig] of its salt can be prepared by subjecting a compound [If] or its salt to elimination reaction of the N-protective group.

15 Suitable salts of the compounds [If] and [Ig] may be acid addition salts as exemplified for the compound [I].

This reaction is carried out in accordance with a conventional method such as hydrolysis, reduction or the like.

20 The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.

Suitable base may include an inorganic base and an organic base such as an alkali metal [e.g. sodium, potassium, etc.], an alkaline earth metal [e.g. magnesium, calcium, etc.], the hydroxide or carbonate or bicarbonate thereof, hydrazine, alkylamine [e.g. methylamine, trimethylamine, triethylamine, etc.], picoline, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo-[5.4.0]undec-7-ene, or the like.

30 Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, hydrogen fluoride, etc.] and an acid addition salt compound [e.g. pyridine hydrochloride, 35 etc.].

The elimination using trihaloacetic acid [e.g. trichloroacetic acid, trifluoroacetic acid, etc.] or the like is preferably carried out in the presence of cation trapping agents [e.g. anisole, phenol, etc.].

5       The reaction is usually carried out in a solvent such as water, an alcohol [e.g. methanol, ethanol, etc.], methylene chloride, chloroform, tetrachloromethane, dioxane, tetrahydrofuran, a mixture thereof or any other solvent which does not adversely influence the reaction. A liquid base or  
10       acid can be also used as the solvent. The reaction temperature is not critical and the reaction is usually carried out under cooling to heating.

      The reduction method applicable for the elimination reaction may include chemical reduction and catalytic  
15       reduction.

      Suitable reducing agents to be used in chemical reduction are a combination of metal [e.g. tin, zinc, iron, etc.] or metallic compound [e.g. chromium chloride, chromium acetate, etc.] and an organic or inorganic acid [e.g. formic  
20       acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.].

      Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts [e.g. platinum  
25       plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.], palladium catalysts [e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.], nickel  
30       catalysts [e.g. reduced nickel, nickel oxide, Raney nickel, etc.], cobalt catalysts [e.g. reduced cobalt, Raney cobalt, etc.], iron catalysts [e.g. reduced iron, Raney iron, etc.], copper catalysts [e.g. reduced copper, Raney copper, Ullman copper, etc.] and the like.

35       In case that the N-protective group is benzyl, the

reduction is preferably carried out in the presence of a combination of palladium catalysts [e.g. palladium black, palladium on carbon, etc.] and formic acid or its salt [e.g. ammonium formate, etc.].

- 5       The reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, N,N-dimethylformamide, or a mixture thereof. Additionally, in case that the above-mentioned acids to be used in chemical reduction are in
- 10   liquid, they can also be used as a solvent. Further, a suitable solvent to be used in catalytic reduction may be the above-mentioned solvent, and other conventional solvent such as diethyl ether, dioxane, tetrahydrofuran, etc. or a mixture thereof.
- 15       The reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to heating.

#### Process 9

- 20       The compound [Ii] or its salt can be prepared by reacting a compound [Ih] or its salt with a compound [XII].
- Suitable salts of the compounds [Ih] and [Ii] may be the same as those exemplified for the compound [I].
- This reaction can be carried out in substantially the
- 25   same manner as Process 7, and therefore the reaction mode and reaction condition [e.g. solvent, reaction temperature, etc.] of this reaction are to be referred to those explained in Process 7.

#### 30   Process 10

- The compound [Ij] or its salt can be prepared by reacting a compound [II] or its salt with a compound [XIII].
- Suitable salts of the compounds [Ij] and [II] may be the same as those exemplified for the compound [I].
- 35       This reaction can be carried out in substantially the

same manner as Process 7, and therefore the reaction mode and reaction condition [e.g. solvent, reaction temperature, etc.] of this reaction are to be referred to those explained in Process 7.

5       The compounds obtained by the above processes can be isolated and purified by a conventional method such as pulverization, recrystallization, column chromatography, reprecipitation, or the like.

10       It is to be noted that the compound [I] and the other compounds may include one or more stereoisomer(s) such as optical isomer(s) or geometrical isomer(s) due to asymmetric carbon atom(s) and double bond(s), and all of such isomers and mixture thereof are included within the scope of this invention.

15       Additionally, it is to be noted that any solvate [e.g. enclosure compound (e.g. hydrate, etc.)] of the compound [I] or a pharmaceutically acceptable salt thereof is also included within the scope of this invention.

20       The object compound [I] and pharmaceutically acceptable salts thereof possess strong potentiation of the cholinergic activity, and are useful for the treatment and/or prevention of disorders in the central nervous system for mammals, and more particularly of amnesia, dementia (e.g., senile dementia, Alzheimer's dementia, dementia associated with various  
25       diseases such as cerebral vascular dementia, cerebral post-traumatic dementia, dementia due to brain tumor, dementia due to chronic subdural hematoma, dementia due to normal pressure hydrocephalus, post-meningitis dementia, Parkinson's disease type dementia, etc.) and the like. Additionally, the object  
30       compound is expected to be useful as therapeutical and/or preventive agents for schizophrenia, depression, stroke, head injury, nicotine withdrawal, spinal cord injury, anxiety, pollakiuria, incontinence of urine, myotonic dystrophy, attention deficit hyperactivity disorder, excessive daytime  
35       sleepiness (narcolepsy), Parkinson's disease or autism.

In order to illustrate the usefulness of the object compound [I], the pharmacological data of the compound [I] is shown in the following.

## 5 Test

### Penile erection in rat

(This test was carried out according to a similar manner to that described in Jpn. J. Pharmacol., Vol. 64, 147-153 (1994))

10

#### (i) Method

Male Fischer 344 rats at the age of 8 weeks (n=7) were used. All rats were handled 3 minutes a day for three successive days before the tests. The rats were tested in  
15 groups of seven and various doses of the test compound were given in semi-randomized order. The test compounds were suspended in 0.5% methyl-cellulose immediately before use, and given intraperitoneally in a volume of 1 ml/kg just before the start of test. Immediately after injection, each  
20 rat was placed in a perspex box (25x25x35 cm) and its behavior was observed for 60 minutes, during which time the number of penile erections was counted. A mirror was situated behind each box to facilitate of the rat. Data was expressed as a mean number.

25

#### (ii) Test Result

Test Compound (Example No.)	Dose (mg/kg)	Penile Erection (number/hr)
2	1	1.14
19	0.32	0.75

30

It is clear that the compound having the above-mentioned

activity ameliorates the memory deficits (i.e. amnesia, dementia, etc.) from the description in the Journal of Pharmacology and Experimental Therapeutics, Vo. 279, No. 3, 1157-1173 (1996). Further, it is expected that the compound  
5 having the above-mentioned activity is useful as  
therapeutical and/or preventive agent for aforesaid diseases from some patent applications (e.g. PCT International Publication No. WO 98/27930, etc.).

For therapeutic purpose, the compound [I] and a  
10 pharmaceutically acceptable salt thereof of the present invention can be used in a form of pharmaceutical preparation containing one of said compounds, as an active ingredient, in admixture with a pharmaceutically acceptable carrier such as an organic or inorganic solid, semi-solid or liquid excipient  
15 suitable for oral or parenteral administration. The pharmaceutical preparations may be capsules, tablets, dragees, granules, suppositories, solution, suspension, emulsion, or the like. If desired, there may be included in these preparations, auxiliary substances, stabilizing agents,  
20 wetting or emulsifying agents, buffers and other commonly used additives.

While the dosage of the compound [I] will vary depending upon the age and condition of the patient, an average single dose of about 0.1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500  
25 mg and 1000 mg of the compound [I] may be effective for treating the above-mentioned diseases. In general, amounts between 0.1 mg/body and about 1,000 mg/body may be administered per day.

30 The following Preparations and Examples are given for the purpose of illustrating this invention.

#### Preparation 1

To a solution of 1-benzyl-4-aminopiperidine (50 g) in  
35 water (360 ml) was added a solution of di-tert-butyl

dicarbonate (61 g) in acetone (360 ml) dropwise under cooling on an ice-water bath. After stirring for 2.5 hours, a precipitate was collected on a filter, washed with water, and dried. The crude product was poured into a mixture of  
5 diisopropyl ether (200 ml) and n-hexane (200 ml) and the mixture was stirred. After filtration, O-tert-butyl N-(1-benzylpiperidin-4-yl)carbamate (66.9 g) was obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.2-1.5 (2H, m), 1.37 (9H, s), 1.66  
10 (2H, br d, J=9.9Hz), 1.91 (2H, br t, J=10.7Hz),  
2.73 (2H, distorted d, J=11.8Hz), 3.2 (1H, m), 3.41  
(2H, s), 6.75 (1H, d, J=7.8Hz), 7.1-7.4 (5H, m)

MASS (APCI) (m/z): 291

#### Preparation 2

15 To a mixture of O-tert-butyl N-(1-benzylpiperidin-4-yl)carbamate (45 g) and 10% palladium on carbon (50% wet, 9 g) in methanol (1 l) was bubbled hydrogen gas under stirring at ambient temperature. The catalyst was removed by glass filter and the solvent was removed under reduced pressure.  
20 After rinse with diisopropyl ether, O-tert-butyl N-(piperidin-4-yl)carbamate (28.35 g) was obtained. The washed solvent was removed under reduced pressure, and the residue was rinsed with diisopropyl ether. The second fraction of O-tert-butyl N-(piperidin-4-yl)carbamate (344 mg)  
25 was obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.18 (2H, ddd, J=3.8, 11.8, 11.8Hz),  
1.37 (9H, s), 1.62 (2H, distorted d, J=10.8Hz),  
1.85 (1H, m), 2.38 (2H, dt, J=2.2, 12.0Hz), 2.86  
30 (2H, distorted d, J=12.3Hz), 3.2 (1H, m), 6.72 (1H, br d)

MASS (APCI) (m/z): 201

#### Preparation 3

To a suspension of O-tert-butyl N-(piperidin-4-yl)carbamate (4.0 g) in dichloromethane (40 ml) were added  
35

pyridine (1.94 ml), dichloromethane (40 ml), acetic anhydride (20.8 ml) and then N,N-dimethylaminopyridine (0.1 g) at ambient temperature. After stirring for 3 hours, the mixture was washed with 0.1N hydrochloric acid, water, and brine.

- 5 After drying with magnesium sulfate, the solvents were removed under reduced pressure. After rinse with diisopropyl ether, O-tert-butyl N-(1-acetylpiperidin-4-yl)carbamate (4.01 g) was obtained.

NMR (DMSO-d<sub>6</sub>, δ): 1.23 (2H, m), 1.38 (9H, s), 1.70  
10 (2H, distorted t, J=11.4Hz), 1.97 (3H, s), 2.64 (1H, br t, J=11.1Hz), 3.04 (1H, dt, J=2.8, 11.5Hz), 3.42 (1H, m), 3.72 (1H, br d, J=15.0Hz), 4.19 (1H, br d, J=13.1Hz), 6.86 (1H, d, J=7.5Hz)

MASS (APCI) (m/z): 243

15

#### Preparation 4

- To a solution of O-tert-butyl N-(1-acetylpiperidin-4-yl)carbamate (2.42 g) in dichloromethane (24 ml) was added 4N hydrogen chloride in dioxane (24 ml). The solvents were  
20 removed under reduced pressure. After rinse with diisopropyl ether, 1-acetyl-4-aminopiperidine hydrochloride (2.02 g) was obtained.

NMR (DMSO-d<sub>6</sub>, δ): 1.41 (2H, m), 1.93 (2H, distorted  
t), 2.00 (3H, s), 2.60 (1H, br t, J=10.4Hz), 3.06  
25 (1H, br t, J=11.3Hz), 3.12 (1H, m), 3.84 (1H, br d, J=14.0Hz), 4.34 (1H, br d, J=13.0Hz), 8.32 (3H, br s)

MASS (APCI) (m/z): 143

30 Preparation 5

- To a solution of phenyl chloroformate (5.64 g) in dichloromethane (70 ml) was added a solution of 4-aminopyridine (2.84 g) and triethylamine (5.02 ml) in dichloromethane (100 ml) dropwise under cooling on an ice-  
35 water bath. After stirring for 1 hour, the solvents were

removed under reduced pressure. A residue was diluted with dichloromethane (200 ml) and water (200 ml). An organic phase was separated and washed with water and brine. After drying with magnesium sulfate, the solvents were removed under reduced pressure. The reaction mixture was diluted with diisopropyl ether and the precipitates were filtered. After rinse with diethyl ether, O-phenyl N-(4-pyridyl)carbamate (5.07 g) was obtained.

NMR (CDCl<sub>3</sub>,  $\delta$ ): 7.17 (2H, m), 7.27 (1H, m), 7.3-7.5

10 (4H, m), 8.50 (2H, dd, J=1.4, 5.0Hz), 8.06 (1H, s)

MASS (APCI) (m/z): 215

#### Preparation 6

A solution of sulfuryl chloride (3.55 ml) in chloroform (45 ml) was added a solution of 1-acetylpiperazine (5.66 mg) and triethylamine (6.16 ml) in chloroform (15 ml) dropwise under cooling on an ice-water bath. After stirring for 6 hours, a precipitate was collected by filtration. After drying over sodium hydroxide, 1-acetylpiperazine-4-sulfonyl chloride (2.43 g) was obtained.

NMR (CDCl<sub>3</sub>,  $\delta$ ): 2.15 (3H, s), 3.35 (4H, m), 3.69 (2H, t, J=5.1Hz), 3.83 (2H, br s)

MASS (APCI) (m/z): 227

#### 25 Preparation 7

To a solution of 1-benzyl-4-aminopiperidine (1.13 g) in dichloromethane (10 ml) were added a solution of 4-fluorobenzoyl chloride (0.99 g) in dichloromethane (1 ml) and diisopropylethylamine (1.09 ml) under cooling on an ice-water bath. The mixture was warmed to ambient temperature slowly under stirring. The mixture was diluted with dichloromethane and washed with water, saturated aqueous sodium hydrogen carbonate, water, and brine. After drying with magnesium sulfate, the solvents were removed under reduced pressure.

35 A residue was purified by column chromatography (silica gel

100 ml, dichloromethane:methanol = 15:1). After rinse with diisopropyl ether - n-hexane (1:1), N-(1-benzylpiperidin-4-yl)-4-fluorobenzamide (1.31 g) was obtained.

5 NMR (DMSO-d<sub>6</sub>, δ): 1.4-1.7 (2H, m), 1.7-1.9 (2H, m),  
2.01 (2H, br t, J=10.7Hz), 2.81 (2H, br d,  
J=11.6Hz), 3.46 (2H, s), 3.73 (1H, m), 7.2-7.4 (7H,  
m), 7.90 (2H, dd, J=5.6, 8.9Hz), 8.26 (1H, br d,  
J=7.7Hz)

10 MASS (APCI) (m/z): 313

#### 10 Preparation 8

The following compound was obtained by using 4-amino-1-benzylpiperidine as a starting compound according to a similar manner to that of Example 2.

15 N-(1-Benzylpiperidin-4-yl)-N'-(4-fluorophenyl)urea

NMR (DMSO-d<sub>6</sub>, δ): 1.25-1.5 (2H, m), 1.7-1.9 (2H, m),  
2.0-2.2 (2H, m), 2.65-2.8 (2H, m), 3.4-3.6 (3H, m),  
6.07 (1H, d, J=7.6Hz), 7.05 (2H, t, J=9Hz), 7.2-  
20 7.45 (2H, m), 8.35 (1H, s)

MASS (APCI) (m/z): 328

#### Preparation 9

25 To a solution of N-(1-benzylpiperidin-4-yl)-N'-(4-fluorophenyl)urea (3.0 g) in a mixture of methanol (15 ml) and tetrahydrofuran (15 ml) was added palladium on carbon (10% w/w, 50% wet, 0.6 g), and the mixture was hydrogenated under atmospheric pressure of hydrogen for 8 hours. The catalyst was filtered off, and the solvents were evaporated  
30 under reduced pressure to give a residue, which was triturated with diisopropyl ether to give N-(piperidin-4-yl)-N'-(4-fluorophenyl)urea (1.97 g).

NMR (DMSO-d<sub>6</sub>, δ): 1.1-1.4 (2H, m), 1.65-1.85 (2H, m),  
2.3-2.65 (2H, m), 2.8-3.0 (2H, m), 3.3-3.7 (1H, m),  
35 6.08 (1H, d, J=8Hz), 7.04 (2H, t, J=9Hz), 7.25-7.5

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.1-1.4 (2H, m), 1.65-1.85 (2H, m),  
2.3-2.65 (2H, m), 2.8-3.0 (2H, m), 3.3-3.7 (1H, m),  
6.08 (1H, d, J=8Hz), 7.04 (2H, t, J=9Hz), 7.25-7.5  
(2H, m), 8.33 (1H, s)

5        MASS (APCI) (m/z): 238

#### Preparation 10

A mixture of N-(1-benzylpiperidin-4-yl)-4-fluorobenzamide (937 mg) and 10% palladium on carbon (50%  
10 wet, 0.2 g) in methanol (20 ml) was stirred under hydrogen  
atmosphere for 7.5 hours at ambient temperature. The  
catalyst was removed by glass filter and the solvent was  
removed under reduced pressure. After rinse with  
diisopropyl ether, N-(piperidin-4-yl)-4-fluorobenzamide (653  
15 mg) was obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.40 (2H, ddd, J=4.0, 11.9, 23.8Hz),  
1.72 (2H, br d, J=9.5Hz), 2.3-2.7 (2H, m), 2.8-3.2  
(2H, m), 3.80 (1H, m), 7.27 (2H, t, J=8.9Hz), 7.92  
(2H, dd, J=5.6, 8.9Hz), 8.26 (1H, d, J=7.7Hz)

20        MASS (APCI) (m/z): 223

#### Example 1

To a solution of O-phenyl N-(4-pyridyl)carbamate (446  
mg) in 1,2-dichloroethane (5 ml) was added a suspension of  
25 1-acetylpiperazine (1.12 g) in 1,2-dichloroethane (20 ml) at  
ambient temperature. The mixture was heated at 60°C with  
stirring for 9 hours. The mixture was cooled to ambient  
temperature, and diluted with dichloromethane and water.  
The aqueous phase was separated and adjusted to pH 11.5 with  
30 sodium hydroxide solution. Excess sodium chloride was added  
to the aqueous solution. The mixture was extracted with a  
mixture of dichloromethane and methanol (about 10:1) and the  
organic phase was washed with brine. After drying with  
magnesium sulfate, the solvents were removed under reduced  
35 pressure. A residue was purified by column chromatography

(silica gel 100 ml, dichloromethane:methanol:aqueous ammonia = 10:1:0.1). After rinse with diisopropyl ether, 1-acetyl-4-(4-pyridylaminocarbonyl)piperazine (398 mg) was obtained.

5 NMR (DMSO-d<sub>6</sub>, δ): 2.03 (3H, s), 3.3-3.6 (8H, m), 7.47 (2H, dd, J=1.5, 4.8Hz), 8.31 (2H, dd, J=1.5, 4.8Hz), 9.01 (1H, s)

MASS (APCI) (m/z): 271

### Example 2

10 To a stirred solution of 1-acetylpiperazine (0.648 g) in tetrahydrofuran (10 ml) was added 4-fluorophenyl isocyanate (0.574 g) at ambient temperature. After stirring at ambient temperature for 1 hour, the solvent was removed by evaporation under reduced pressure, and the residue was  
15 triturated with diisopropyl ether to give 1-acetyl-4-(4-fluorophenylcarbamoyl)piperazine (1.25 g).

NMR (DMSO-d<sub>6</sub>, δ): 2.03 (3H, s), 3.3-3.6 (8H, m), 7.07 (2H, t, J=9Hz), 7.46 (2H, dd, J=5, 9Hz), 8.61 (1H, s)

20 MASS (APCI) (m/z): 266

### Example 3

The following compound was obtained by using 1-tert-butoxycarbonylpiperazine as a starting compound according to  
25 a similar manner to that of Example 2.

1-tert-Butoxycarbonyl-4-(4-fluorophenylcarbamoyl)-piperazine

30 NMR (DMSO-d<sub>6</sub>, δ): 1.42 (9H, s), 3.25-3.5 (8H, m), 7.07 (2H, t, J=9Hz), 7.45 (2H, dd, J=5, 9Hz), 8.60 (1H, s)

MASS (LD) (m/z): 346.2

### Example 4

35 To a solution of pyridine-4-carboxylic acid (1.0 g) and

triethylamine (1.2 ml) in toluene (20 ml) was added  
diphenylphosphoryl azide (1.75 ml) at ambient temperature.  
The resulting mixture was heated to reflux for 30 minutes  
and cooled to 0°C. To the mixture was added 1-tert-  
5 butoxycarbonylpiperazine (1.51 g), and the mixture was  
allowed to heat to 90°C for 1 hour. After cooling to ambient  
temperature, the reaction mixture was taken up into ethyl  
acetate, washed in turn with water and brine, dried over  
magnesium sulfate, and evaporated under reduced pressure.  
10 The residue was chromatographed on silica gel (150 ml)  
eluting with 0-7% methanol in dichloromethane. Trituration  
with a mixture of diisopropyl ether and ethanol gave 1-tert-  
butoxycarbonyl-4-(pyridin-4-ylcarbonyl)piperazine (0.66 g).  
NMR (DMSO-d<sub>6</sub>, δ): 1.42 (9H, s), 3.25-3.5 (8H, m), 7.46  
15 (2H, d, J=1.5, 5Hz), 8.30 (2H, d, J=1.5, 5Hz),  
9.00 (1H, s)  
MASS (LD) (m/z): 307.2

#### Example 5

20 To a suspension of 1-acetyl-4-aminopiperidine  
hydrochloride (0.4 g) in dichloromethane (5 ml) were added  
in turn pyridine (0.54 ml) and 4-fluorophenyl chloroformate  
(0.29 ml) at 0°C. The mixture was allowed to warm to ambient  
temperature and stirred for 1 hour, which was taken up into  
25 a mixture of water and ethyl acetate. The separated organic  
layer was washed in turn with hydrochloric acid (1N),  
aqueous sodium hydrogen carbonate, and brine, and dried over  
magnesium sulfate. Evaporation under reduced pressure gave  
a residue, which was triturated with diisopropyl ether to  
30 give 1-acetyl-4-(4-fluorophenoxycarbonylamino)piperidine  
(347 mg).

NMR (DMSO-d<sub>6</sub>, δ): 1.15-1.55 (2H, m), 1.7-1.95 (2H, m),  
2.00 (3H, s), 2.65-2.85 (1H, m), 3.0-3.25 (1H, m),  
3.5-3.7 (1H, m), 3.7-3.9 (1H, m), 4.15-4.3 (1H, m),  
35 7.05-7.3 (4H, m), 7.86 (1H, d, J=8Hz)

MASS (APCI) (m/z): 281

Example 6

To a suspension of 1-acetyl-4-aminopiperidine  
5 hydrochloride (715 mg) in dichloromethane (7 ml) were added  
diisopropylethylamine (1.83 ml) and a solution of  
4-fluorobenzoyl chloride (0.83 mg) in dichloromethane (2 ml)  
at ambient temperature. After stirring for 6.5 hours, the  
reaction mixture was diluted with dichloromethane and washed  
10 with water, saturated aqueous sodium hydrogen carbonate, and  
brine. After drying with magnesium sulfate, the solvents  
were removed under reduced pressure. A residue was purified  
by column chromatography (silica gel 50 ml,  
dichloromethane:methanol = 50:1 to 10:1). After rinse with  
15 diisopropyl ether, N-(1-acetylpiperidin-4-yl)-4-  
fluorobenzamide (738 mg) was obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.40 (2H, m), 1.81 (2H, distorted t,  
J=12.4Hz), 2.01 (3H, s), 2.68 (1H, br t, J=11.4Hz),  
3.13 (1H, br t, J=11.6Hz), 3.83 (1H, br t,  
20 J=13.9Hz), 4.01 (1H, m), 4.33 (1H, br d, J=13.7Hz),  
7.29 (2H, t, J=8.9Hz), 7.92 (2H, dd, J=5.5, 8.8Hz),  
8.31 (1H, d, J=7.7Hz)

MASS (APCI) (m/z): 265

25 Example 7

To a suspension of 1-acetyl-4-aminopiperidine  
hydrochloride (536 mg) in dichloromethane (5 ml) were added  
isonicotinoyl chloride hydrochloride (534 mg) and  
diisopropylethylamine (1.05 ml) at ambient temperature.  
30 After stirring for 8 hours, the reaction mixture was poured  
into water and diluted with dichloromethane. The mixture  
was adjusted to pH 8.5 with 1N sodium hydroxide solution.  
Sodium chloride was added to the mixture and an organic  
phase was separated. The aqueous phase was extracted with  
35 dichloromethane and a combined organic phase was dried over

magnesium sulfate. The solvents were removed under reduced pressure. A residue was purified by column chromatography (silica gel 50 ml, dichloromethane:methanol = 10:1). After crystallization from diisopropyl ether:n-hexane,

- 5 N-(1-acetylpiperidin-4-yl)-N-isonicotinamide (477 mg) was obtained.

NMR (DMSO- $d_6$ ,  $\delta$ ): 1.4 (2H, m), 1.83 (2H, distorted t, J=11Hz), 2.01 (3H, s), 2.69 (1H, br t, J=11Hz), 3.14 (1H, br t, J=12Hz), 3.83 (1H, br d, J=14.1Hz),  
10 4.03 (1H, m), 4.33 (1H, br d, J=13.1Hz), 7.75 (2H, dd, J=1.7, 4.4Hz), 8.62 (1H, d, J=7.5Hz), 8.72 (2H, dd, J=1.6, 4.4Hz)

MASS (APCI) (m/z): 248

15 Example 8

To a suspension of 1-acetyl-4-aminopiperidine hydrochloride (715 mg) in dichloromethane (7 ml) were added diisopropylethylamine (1.83 ml) and a solution of 4-fluorobenzenesulfonyl chloride (0.83 mg) in  
20 dichloromethane (2 ml) at ambient temperature. After stirring for 6.5 hours, the reaction mixture was diluted with dichloromethane and washed with water, saturated aqueous sodium hydrogen carbonate, and brine. After drying with magnesium sulfate, the solvents were removed under  
25 reduced pressure. A residue was purified by column chromatography (silica gel 50 ml, dichloromethane:methanol = 50:1 to 20:1). After rinse with diisopropyl ether, N-(1-acetylpiperidin-4-yl)-4-fluorobenzenesulfonamide (859 mg) was obtained.

30 NMR (DMSO- $d_6$ ,  $\delta$ ): 1.21 (2H, m), 1.54 (2H, m), 1.94 (3H, s), 2.66 (1H, br t, J=10.8Hz), 3.02 (1H, dt, J=2.9, 12.0Hz), 3.22 (1H, m), 3.64 (1H, br d, J=14.0Hz), 4.05 (1H, br d, J=13.2Hz), 7.44 (2H, t, J=8.9Hz), 7.8-8.0 (3H, m)

35 MASS (APCI) (m/z): 301

Example 9

To a solution of O-phenyl N-(4-pyridyl)carbamate (0.81 g) in chloroform (10 ml) were added 1-acetyl-4-aminopiperidine hydrochloride (0.68 g) and triethylamine (1.06 ml) at ambient temperature. After stirring for 1 day, the mixture changed to a solution. The solvents were removed under reduced pressure. A residue was purified by column chromatography (silica gel 100 ml, dichloromethane:methanol = 10:1 to 5:1, and silica gel 50 ml, dichloromethane:methanol:aqueous ammonia = 10:1:0.1). The solvents of desired fractions were removed under reduced pressure. A residue was dissolved with methanol (5 ml) and dichloromethane (5 ml), and 4N hydrogen chloride in dioxane (1.5 ml) was added to the solution. The solvents were removed under reduced pressure, and the residue was evaporated azeotropically with methanol. After crystallization from diisopropyl ether and n-hexane, N-(1-acetylpiperidin-4-yl)-N'-(4-pyridyl)urea (343 mg) was obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.1-1.6 (2H, m), 1.77 (2H, m), 2.01 (3H, s), 2.94 (1H, br t, J=10.4Hz), 3.22 (1H, br t, J=10.1Hz), 3.76 (2H, m), 4.05 (1H, d, J=13.6Hz), 7.60 (1H, d, J=7.8Hz), 7.83 (2H, d, J=6.8Hz), 8.52 (2H, d, J=7.1Hz), 11.21 (1H, s), 14.66 (1H, br s)

MASS (APCI) (m/z): 263

Example 10

To a suspension of 1-acetyl-4-aminopiperidine hydrochloride (536 mg) in dichloromethane (5 ml) were added 4-fluorophenyl isocyanate (375  $\mu$ l) and diisopropylethylamine (575  $\mu$ l) at ambient temperature. After stirring for 3 hours, the reaction mixture was diluted with dichloromethane. An organic phase was separated and an aqueous phase was extracted with dichloromethane. A combined organic phase was dried over magnesium sulfate and the solvents were

removed under reduced pressure. After crystallization from diisopropyl ether and n-hexane, N-(1-acetylpiperidin-4-yl)-N'-(4-fluorophenyl)urea (448 mg) was obtained.

5 NMR (DMSO-d<sub>6</sub>, δ): 1.1-1.5 (2H, m), 1.80 (2H, distorted t, J=10Hz), 2.00 (3H, s), 2.77 (1H, br d, J=10.8Hz), 3.14 (1H, br d, J=11.1Hz), 3.5-3.9 (2H, m), 4.16 (1H, br d, J=13.2Hz), 6.15 (1H, d, J=7.6Hz), 7.05 (2H, t, J=8.9Hz), 7.40 (2H, dd, J=5.0, 9.2Hz), 8.37 (1H, s)  
10 MASS (APCI) (m/z): 280

#### Example 11

To a solution of 4-(4-fluorobenzoylamino)piperidine (0.25 g) in dichloromethane (5 ml) were added in turn  
15 pyridine (0.14 ml) and methyl chloroformate (87 μl) at 0°C. The mixture was allowed to warm to ambient temperature and stirred for 1 hour. To the mixture was added N,N-dimethylaminopyridine (0.13 g) and allowed to stir for another 1 hour. The reaction mixture was taken up into a  
20 mixture of water and ethyl acetate. The separated organic layer was washed in turn with hydrochloric acid (1N), aqueous sodium hydrogen carbonate, and brine, and dried over magnesium sulfate. Evaporation under reduced pressure gave a residue, which was triturated with diisopropyl ether to  
25 give 4-(4-fluorobenzoylamino)-1-methoxycarbonylpiperidine (0.265 g).

NMR (DMSO-d<sub>6</sub>, δ): 1.3-1.6 (2H, m), 1.75-1.9 (2H, m), 2.8-3.05 (2H, m), 3.60 (3H, s), 3.85-4.1 (2H, m), 7.29 (2H, t, J=9Hz), 7.90 (2H, dd, J=6, 9Hz), 8.30  
30 (1H, d, J=8Hz)  
MASS (APCI) (m/z): 281

#### Example 12

To a solution of 4-(4-fluorobenzoylamino)piperidine  
35 (0.25 g) in pyridine (5 ml) were added in turn

4-trifluorobenzenesulfonyl chloride (0.219 g) and catalytic amount of N,N-dimethylaminopyridine at 0°C.

The mixture was allowed to warm to ambient temperature and stirred for 1 hour, which was taken up into a mixture of  
5 water and dichloromethane. The separated organic layer was washed in turn with hydrochloric acid (1N), aqueous sodium hydrogen carbonate, and brine, and dried over magnesium sulfate. Evaporation under reduced pressure gave a residue, which was triturated with diisopropyl ether to give  
10 4-(4-fluorobenzoylamino)-1-(4-trifluorophenylsulfonyl)-piperidine (0.38 g).

NMR (DMSO-d<sub>6</sub>, δ): 1.45-1.7 (2H, m), 1.8-1.95 (2H, m),  
2.35-2.55 (2H, m), 3.5-3.85 (3H, m), 7.28 (2H, t, J=9Hz), 7.50 (2H, t, J=9Hz), 7.75-7.95 (4H, m),  
15 8.31 (1H, d, J=8Hz)

MASS (APCI) (m/z): 381

### Example 13

To a solution of 4-(4-fluorobenzoylamino)piperidine  
20 (0.15 g) in dichloromethane (5 ml) were added in turn pyridine (82 μl) and 4-trifluoromethoxybenzoyl chloride (106 μl) at 0°C. The mixture was allowed to warm to ambient temperature and stirred for 4 hours, which was taken up into a mixture of water and dichloromethane. The separated  
25 organic layer was washed in turn with hydrochloric acid (1N), aqueous sodium hydrogen carbonate, and brine, and dried over magnesium sulfate. Evaporation of the solvent under reduced pressure gave 4-(4-fluorobenzoylamino)-1-(4-trifluoromethoxybenzoyl)piperidine (205 mg).

30 NMR (DMSO-d<sub>6</sub>, δ): 1.3-1.7 (2H, m), 1.7-2.0 (2H, m),  
2.7-3.4 (2H, m), 3.4-3.8 (1H, m), 3.9-4.2 (1H, m),  
4.2-4.6 (1H, m), 7.30 (2H, t, J=9Hz), 7.35-7.6 (4H, m), 7.91 (2H, dd, J=6, 9Hz), 8.35 (1H, d, J=8Hz)

MASS (LD) (m/z): 433.2

Example 14

To a solution of 4-(4-fluorobenzoylamino)piperidine (0.15 g) in dichloromethane (5 ml) were added in turn pyridine (0.14 ml) and methanesulfonyl chloride (96  $\mu$ l) at 0°C. The mixture was allowed to warm to ambient temperature and stirred for 1 hour. To the mixture was added N,N-dimethylaminopyridine (0.13 g) and allowed to stir for another 1 hour. The reaction mixture was taken up into a mixture of water and dichloromethane. The separated organic layer was washed in turn with hydrochloric acid (1N), aqueous sodium hydrogen carbonate, and brine, and dried over magnesium sulfate. Evaporation under reduced pressure gave a residue, which was triturated with diisopropyl ether to give 4-(4-fluorobenzoylamino)-1-methylsulfonylpiperidine (0.30 g).

NMR (DMSO- $d_6$ ,  $\delta$ ): 1.45-1.7 (2H, m), 1.8-2.05 (2H, m), 2.7-2.95 (2H, m), 2.88 (3H, s), 3.5-3.65 (2H, m), 3.8-4.05 (1H, m), 7.30 (2H, t, J=9Hz), 7.91 (2H, dd, J=6, 9Hz), 8.36 (1H, d, J=8Hz)

MASS (APCI) (m/z): 301

Example 15

To a solution of N-(piperidin-4-yl)-N'-(4-fluorophenyl)urea (0.3 g) in tetrahydrofuran (4 ml) were added in turn pyridine (0.28 ml), methyl chloroformate (98  $\mu$ l) and catalytic amount of N,N-dimethylaminopyridine at 0°C. The mixture was allowed to warm to ambient temperature and stirred for 2 hours. The reaction mixture was taken up into a mixture of water and ethyl acetate. The separated organic layer was washed in turn with hydrochloric acid (1N), aqueous sodium hydrogen carbonate, and brine, and dried over magnesium sulfate. Evaporation under reduced pressure gave a residue, which was triturated with diisopropyl ether to give N-(1-methoxycarbonylpiperidin-4-yl)-N'-(4-fluorophenyl)urea (0.312 g).

NMR (DMSO-d<sub>6</sub>, δ): 1.1-1.4 (2H, m), 1.7-1.9 (2H, m),  
2.8-3.1 (2H, m), 3.5-3.75 (1H, m), 3.59 (3H, s),  
3.75-3.95 (2H, m), 6.15 (1H, d, J=7.6Hz), 7.05 (2H,  
t, J=9Hz), 7.37 (2H, dd, J=5, 9Hz), 8.37 (1H, s)

5        MASS (APCI) (m/z): 296

#### Example 16

To a solution of N-(piperidin-4-yl)-N'-(4-fluorophenyl)urea (0.3 g) in tetrahydrofuran (4 ml) were  
10        added in turn N,N-dimethylaminopyridine (0.23 g) and  
4-fluorobenzenesulfonyl chloride (0.25 g) at 0°C. The  
mixture was allowed to warm to ambient temperature and  
stirred for 1 hour. The reaction mixture was taken up into  
a mixture of water and dichloromethane. The separated  
15        organic layer was washed in turn with hydrochloric acid (1N),  
aqueous sodium hydrogen carbonate, and brine, and dried over  
magnesium sulfate. Evaporation under reduced pressure gave  
a residue, which was triturated with diisopropyl ether to  
give N-(1-(4-fluorophenylsulfonyl)-  
20        piperidin-4-yl)-N'-(4-fluorophenyl)urea (0.468 g).

NMR (DMSO-d<sub>6</sub>, δ): 1.3-1.6 (2H, m), 1.75-1.95 (2H, m),  
2.45-2.7 (2H, m), 3.35-3.6 (3H, m), 6.14 (1H, d,  
J=7.5Hz), 7.03 (2H, t, J=9Hz), 7.34 (2H, dd, J=5,  
9Hz), 7.50 (2H, t, J=9Hz), 7.75-7.95 (2H, m), 8.31  
25        (1H, s)

MASS (APCI) (m/z): 396

#### Example 17

To a suspension of N-(piperidin-4-yl)-4-fluorobenzamide  
30        (0.5 g) in dichloromethane (5 ml) were added pyridine (218  
μl), dichloromethane (5 ml) and benzoyl chloride (290 μl) at  
ambient temperature. After stirring for 3.5 hours, water (5  
ml) was poured into the mixture. An organic layer was  
separated, and washed with water and brine. After drying  
35        with magnesium sulfate, the solvents were removed under

reduced pressure. A residue was purified by column chromatography (silica gel, toluene:ethyl acetate = 1:1 to ethyl acetate). After rinse with diisopropyl ether, N-(1-benzoylpiperidin-4-yl)-4-fluorobenzamide (515 mg) was  
5 obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.50 (2H, br s), 1.85 (2H, br s),  
2.8-3.3 (2H, m), 3.61 (1H, m), 4.1 (1H, m), 4.35  
(1H, m), 7.29 (2H, t, J=8.9Hz), 7.3-7.5 (5H, m),  
7.92 (2H, dd, J=5.6, 8.9Hz), 8.34 (1H, d, J=7.9Hz)  
10 MASS (APCI) (m/z): 327

#### Example 18

To a suspension of N-(piperidin-4-yl)-4-fluorobenzamide (556 mg) in dichloromethane (5 ml) were added pivaloyl  
15 chloride (0.37 ml), pyridine (0.24 ml) and  
N,N-dimethylaminopyridine (25 mg) at ambient temperature.  
After stirring for 1 day, the mixture was diluted with  
dichloromethane, and washed with water and brine. After  
drying with magnesium sulfate, the solvents were removed  
20 under reduced pressure. After trituration with diisopropyl  
ether, N-(1-pivaloylpiperidin-4-yl)-4-fluorobenzamide (305  
mg) was obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.20 (9H, s), 1.41 (2H, m), 1.7-1.9  
(2H, m), 2.91 (2H, br t, J=11.9Hz), 4.07 (1H, m),  
25 4.27 (2H, br d, J=13.3Hz), 7.29 (2H, t, J=8.9Hz),  
7.92 (2H, dd, J=5.5, 8.9Hz), 8.30 (1H, d, J=7.8Hz)

MASS (APCI) (m/z): 329

#### Example 19

To a suspension of N-(piperidin-4-yl)-4-fluorobenzamide (556 mg) in dichloromethane (6 ml) were added  
30 cyclopropanecarboxylic acid (0.20 ml), 1-  
hydroxybenzotriazole (338 mg) and 1-ethyl-3-(3-  
dimethylaminopropyl)carbodiimide hydrochloride (480 mg) at  
35 ambient temperature. After stirring for 21 hours, the

mixture was diluted with dichloromethane, and washed with water, saturated aqueous sodium hydrogen carbonate, and brine. After drying with magnesium sulfate, the solvents were removed under reduced pressure. After crystallization from diisopropyl ether, N-(1-cyclopropylcarbonylpiperidin-4-yl)-4-fluorobenzamide (627 mg) was obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 0.6-0.8 (4H, m), 1.2-1.6 (2H, m), 1.7-2.0 (2H, m), 1.85 (1H, m), 2.72 (1H, m), 3.21 (1H, m), 4.04 (1H, m), 4.30 (2H, m), 7.29 (2H, t, J=8.9Hz), 7.92 (2H, dd, J=5.6, 8.9Hz), 8.31 (1H, d, J=7.7Hz)

MASS (APCI) (m/z): 313

#### Example 20

1-tert-Butoxycarbonyl-4-(4-fluorophenylcarbamoyl)-piperazine (0.30 g) was dissolved in a solution of hydrogen chloride in ethyl acetate (4N, 2 ml), and the solution was stirred at ambient temperature for 1 hour. The solvent was removed by evaporation under reduced pressure to give 1-(4-fluorophenylcarbamoyl)piperazine as a white powder, which was taken up into dichloromethane (3 ml), and to the mixture were added in turn pyridine (0.25 ml), 4-trifluoromethoxybenzoyl chloride (0.146 ml), and catalytic amount of N,N-dimethylaminopyridine. After stirring at ambient temperature for 12 hours, the mixture was washed in turn with hydrochloric acid (0.5N), aqueous sodium hydrogen carbonate, and brine, dried over magnesium sulfate, and evaporated under reduced pressure. The residue was chromatographed on silica gel (50 ml) eluting with 0%-3% methanol in dichloromethane to give 1-(4-fluorophenylcarbamoyl)-4-(4-trifluoromethoxybenzoyl)-piperazine (0.19 g).

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 3.2-3.8 (8H, m), 7.08 (2H, t, J=9Hz), 7.35-7.5 (4H, m), 7.5-7.65 (2H, m)

MASS (LD) (m/z): 434.1

Example 21

The following compound was obtained by using methyl chloroformate as a reactive derivative at the carboxy group according to a similar manner to that of Example 20.

5

1-Methoxycarbonyl-4-(4-fluorophenylcarbamoyl)piperazine

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 3.3-3.5 (8H, m), 3.62 (3H, s), 7.07  
(2H, t, J=9Hz), 7.44 (2H, dd, J=5, 9Hz), 8.62 (1H,  
s)

10

MASS (APCI) (m/z): 282

Example 22

A mixture of N-acetylpiperidine-4-carboxylic acid (514 mg), 1-hydroxybenzotriazole (405 mg), 1-ethyl-3-(3-  
15 dimethylaminopropyl)carbodiimide hydrochloride (575 mg) and  
4-fluoroaniline (284.2 ml) in dichloromethane (5 ml) was  
stirred for 18 hours at ambient temperature. The mixture  
was diluted with dichloromethane and washed with water,  
saturated aqueous sodium hydrogen carbonate, water, and  
20 brine. After drying with magnesium sulfate, the solvents  
were removed under reduced pressure. A residue was purified  
by column chromatography (silica gel 40 ml,  
dichloromethane:methanol = 15:1). After trituration with  
diisopropyl ether, 1-acetyl-4-(4-fluorophenyl)-  
25 carbamoylpiperidine (532 mg) was obtained.

NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.3-1.7 (2H, m), 1.8 (2H, m), 2.01  
(3H, s), 2.5 (2H, m), 3.05 (1H, br t, J=10.6Hz),  
3.87 (1H, br d, J=14.1Hz), 4.40 (1H, br d,  
J=13.1Hz), 7.12 (2H, t, J=8.9Hz), 7.61 (2H, dd,  
30 J=5.1, 9.1Hz), 9.96 (1H, s)

MASS (APCI) (m/z): 265

Example 23

A solution of 1-acetylpiperazine-4-sulfonyl chloride  
35 (0.91 g) in chloroform (10 ml) were added 4-fluoroaniline

(0.38 ml) and triethylamine (0.56 ml) at ambient temperature. After stirring for 6 days, the solvents were removed under reduced pressure. A residue was purified by column chromatography (silica gel 100 ml, dichloromethane:methanol = 19:1). After rinse with diisopropyl ether, 1-acetyl-4-(4-fluorophenyl)-sulfamoylpiperazine (716 mg) was obtained.

NMR (CDCl<sub>3</sub>,  $\delta$ ): 1.97 (3H, s), 3.09 (4H, m), 3.37 (4H, m), 7.20 (4H, m), 10.00 (1H, s)

10 MASS (APCI) (m/z): 302

#### Example 24

To a solution of O-tert-butyl (1-acetylpiperidin-4-yl)carbamate (0.97 g) in N,N-dimethylformamide (10 ml) was added 60% sodium hydride (0.18 g) at ambient temperature. After stirring for 40 minutes, 4-fluorobenzyl bromide (0.6 ml) was added to the reaction mixture. After additional stirring for 4 hours, the reaction mixture was poured into a mixture of ethyl acetate (50 ml) and water (10 ml). An organic phase was separated and washed with water and brine. After drying with magnesium sulfate, the solvents were removed under reduced pressure. A residue was purified by column chromatography (silica gel 100 ml, toluene:ethyl acetate = 1:1 to 1:2). After crystallization from diisopropyl ether and n-hexane, O-tert-butyl N-(4-fluorobenzyl)-N-(1-acetylpiperidin-4-yl)carbamate (922 mg) was obtained.

30 NMR (DMSO-d<sub>6</sub>,  $\delta$ ): 1.35 (9H, br s), 1.3-1.8 (4H, m), 1.95 (3H, s), 2.3-2.6 (1H, m), 2.97 (1H, m), 3.80 (1H, br d, J=15.2Hz), 4.0 (1H, m), 4.32 (2H, s), 4.2-4.6 (1H, m), 7.0-7.4 (4H, m).

MASS (APCI) (m/z): 295

#### Example 25

35 To a solution of O-tert-butyl N-(4-fluorobenzyl)-N-(1-

acetylpiperidin-4-yl)carbamate (0.5 g) in dichloromethane (5 ml) was added 4N hydrogen chloride in dioxane (5 ml). The reaction mixture was diluted with diisopropyl ether and the precipitates were collected by filtration. After drying  
5 under reduced pressure, 1-acetyl-4-(4-fluorobenzyl)-aminopiperidine hydrochloride (409 mg) was obtained.

NMR (DMSO- $d_6$ +D<sub>2</sub>O,  $\delta$ ): 1.54 (2H, m), 2.02 (3H, s),  
2.0-2.3 (2H, m), 2.4-2.7 (1H, m), 3.04 (1H, br t, J=12.1Hz), 3.29 (1H, m), 3.9 (1H, m), 4.17 (2H, s),  
10 4.44 (1H, br d, J=13.6Hz), 7.27 (2H, t, J=8.9Hz),  
7.66 (2H, br t, J=6.8Hz)

MASS (APCI) (m/z): 251

#### Example 26

15 To a solution of N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide (529 mg) in N,N-dimethylformamide (5 ml) was added sodium hydride (0.1 g). After stirring for 45 minutes, methyl iodide (623 ml) was added to the solution. After  
20 stirring for 45 minutes, the mixture was diluted with ethyl acetate (100 ml) and water (50 ml). An organic phase was separated, and washed with water and brine. After drying with magnesium sulfate, the solvents were removed under reduced pressure. After trituration with diisopropyl ether, N-(1-acetylpiperidin-4-yl)-N-methyl-4-fluorobenzamide (248  
25 mg) was obtained.

NMR (DMSO- $d_6$ ,  $\delta$ ): 1.65 (4H, m), 2.00 (3H, s), 2.78 (3H, s), 3.8 (1H, m), 4.4 (1H, m), 2.0-4.6 (3H, br m), 7.26 (2H, t, J=8.9Hz), 7.46 (2H, dd, J=5.6, 8.7Hz)

30 MASS (APCI) (m/z): 301

#### Example 27

A suspension of 1-acetylpiperazine (0.627 g), 2-chloro-4'-fluoroacetophenone (0.844 g), and potassium hydrogen  
35 carbonate (0.735 g) in acetonitrile (12 ml) was stirred at

ambient temperature for 3 days. After removal of the solid by filtration, the filtrate was evaporated under reduced pressure to give a residue, which was chromatographed on silica gel (100 ml) eluting with 0%-5% methanol in dichloromethane. The objective compound of the free form was taken up into ethyl acetate (2 ml) and to the solution was added a solution of hydrogen chloride in ethyl acetate (4N, 2 ml). The resulting precipitate was collected by filtration, washed with diisopropyl ether, and dried in vacuo to give 1-acetyl-4-(4-fluorophenylcarbonylmethyl)-piperazine hydrochloride (1.47 g).


NMR (DMSO- $d_6$ ,  $\delta$ ): 2.06 (3H, s), 2.95-3.8 (6H, m), 3.9-4.15 (1H, m), 4.2-4.45 (1H, m), 5.13 (2H, s), 7.48 (2H, t,  $J=9\text{Hz}$ ), 8.09 (2H, dd,  $J=5, 9\text{Hz}$ )

MASS (APCI) (m/z): 265

## C L A I M S

1. A compound of the formula:

5



wherein  $\text{R}^1$  is acyl,

10

$\text{R}^2$  is lower alkyl, lower alkoxy, lower  
alkylamino, lower alkenyl, lower  
alkenyloxy, lower alkenylamino, lower  
alkynyl, lower alkynyloxy, lower  
alkynylamino, cyclo(lower)alkyl,  
15 cyclo(lower)alkyloxy,  
cyclo(lower)alkylamino, aryl, aryloxy,  
arylamino, a heterocyclic group or amino  
substituted with a heterocyclic group,  
each of which may be substituted with  
20 suitable substituent(s); or acyl;

A is a single bond,  $\text{-}\overset{\text{O}}{\parallel}\text{C-}$  or  $\text{-SO}_2\text{-}$ ,

E is lower alkylene optionally substituted with  
suitable substituent(s),

25

X is CH or N,

Y is a single bond, lower alkylene or  $\text{-}\overset{\text{R}^5}{\underset{|}{\text{N}}}\text{-}$   
(wherein  $\text{R}^5$  is hydrogen, lower alkyl,  
substituted-lower alkyl, an N-protective  
group, aryl, acyl or a heterocyclic group),

30

Q is  $\text{-CH}_2\text{-}$ ,  $\text{-}\overset{\text{O}}{\parallel}\text{C-}$ ,  $\text{-SO}_2\text{-}$  or  $\text{-N=CH-}$ , and

$\text{R}^3$  and  $\text{R}^4$  are each hydrogen or lower alkyl, or  
are taken together to form lower alkylene  
optionally condensed with a cyclic  
35 hydrocarbon or a heterocyclic ring,

provided that when X is N,

then 1) Y is a single bond, and

Q is  $-\text{CH}_2-$ ,  $-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-$  or  $-\text{SO}_2-$ , or

5 2) Y is lower alkylene,  
and pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, wherein  
R<sup>2</sup> is aryl, aryloxy or arylamino, each aryl of which  
10 may be substituted with halogen; pyridyl; or  
pyridylamino;

A is a single bond,

E is ethylene,

X is CH or N,

15 Y is a single bond, lower alkylene or  $-\overset{\text{R}^5}{\underset{|}{\text{N}}}-$   
(wherein R<sup>5</sup> is hydrogen, lower alkyl or  
an N-protective group),

Q is  $-\text{CH}_2-$ ,  $-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-$  or  $-\text{SO}_2-$ , and

20 R<sup>3</sup> and R<sup>4</sup> are taken together to form ethylene.

3. A compound according to claim 2, wherein  
R<sup>1</sup> is lower alkanoyl, esterified carboxy, substituted  
or unsubstituted aroyl, lower alkylsulfonyl,  
25 substituted or unsubstituted arylsulfonyl, or  
cyclo(lower)alkylcarbonyl, and  
R<sup>2</sup> is aryl or arylamino, each aryl of which may be  
substituted with halogen.

- 30 4. A compound according to claim 3, wherein  
R<sup>1</sup> is lower alkanoyl, lower alkoxycarbonyl, aroyl,  
aroyl substituted with halo(lower)alkoxy, lower  
alkylsulfonyl, arylsulfonyl, arylsulfonyl  
substituted with halogen, or  
35 cyclo(lower)alkylcarbonyl,

X is CH,  
 Y is a single bond or  $\begin{array}{c} \text{H} \\ | \\ -\text{N}- \end{array}$ , and

5 Q is  $\begin{array}{c} \text{O} \\ || \\ -\text{C}- \end{array}$  or  $-\text{SO}_2-$ .

5. A compound according to claim 3, wherein  
 R<sup>1</sup> is lower alkanoyl, lower alkoxy carbonyl, aroyl,  
 10 aroyl substituted with halo(lower)alkoxy, lower  
 alkylsulfonyl, arylsulfonyl, arylsulfonyl  
 substituted with halogen, or  
 cyclo(lower)alkylcarbonyl,

X is N,  
 Y is a single bond or lower alkylene, and  
 15 Q is  $\begin{array}{c} \text{O} \\ || \\ -\text{C}- \end{array}$  or  $-\text{SO}_2-$ .

6. A compound according to claim 4, wherein


20 Y is  $\begin{array}{c} \text{H} \\ | \\ -\text{N}- \end{array}$ , and  
 Q is  $\begin{array}{c} \text{O} \\ || \\ -\text{C}- \end{array}$ .

7. A compound according to claim 5, wherein  
 25 Y is a single bond, and

Q is  $\begin{array}{c} \text{O} \\ || \\ -\text{C}- \end{array}$ .

8. A process for preparing a compound of the formula:

30



wherein R<sup>1</sup> is acyl,

5  $R^2$  is lower alkyl, lower alkoxy, lower  
alkylamino, lower alkenyl, lower  
alkenyloxy, lower alkenylamino, lower  
alkynyl, lower alkynyloxy, lower  
alkynylamino, cyclo(lower)alkyl,  
cyclo(lower)alkyloxy,  
cyclo(lower)alkylamino, aryl, aryloxy,  
arylamino, a heterocyclic group or amino  
substituted with a heterocyclic group,  
10 each of which may be substituted with  
suitable substituent(s); or acyl;

A is a single bond,  $\overset{\text{O}}{\parallel}{\text{C}}-$  or  $-\text{SO}_2-$ ,  
E is lower alkylene optionally substituted with  
15 suitable substituent(s),

X is CH or N,  
Y is a single bond, lower alkylene or  $-\overset{\text{R}^5}{\underset{|}{\text{N}}}-$   
(wherein  $R^5$  is hydrogen, lower alkyl,  
substituted-lower alkyl, an N-protective  
20 group, aryl, acyl or a heterocyclic group),

Q is  $-\text{CH}_2-$ ,  $\overset{\text{O}}{\parallel}{\text{C}}-$ ,  $-\text{SO}_2-$  or  $-\text{N}=\text{CH}-$ , and  
 $R^3$  and  $R^4$  are each hydrogen or lower alkyl, or  
are taken together to form lower alkylene  
optionally condensed with a cyclic  
25 hydrocarbon or a heterocyclic ring,

provided that when X is N,

then 1) Y is a single bond, and

30 Q is  $-\text{CH}_2-$ ,  $\overset{\text{O}}{\parallel}{\text{C}}-$  or  $-\text{SO}_2-$ , or  
2) Y is lower alkylene,

or pharmaceutically acceptable salt thereof,  
which comprises,


35 1) reacting a compound of the formula:

5




or its salt with a compound of the formula:

10



or its reactive derivative at the carboxy or sulfo group, or a salt thereof to provide a compound of the formula:

15



or its salt, in the above formulas,  
 $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ , A and E are each as defined above, and  
20  $\text{Q}_a$  is  $\begin{array}{c} \text{O} \\ || \\ -\text{C}- \end{array}$  or  $-\text{SO}_2-$ , or

2) reacting a compound of the formula:

25




or its salt with a compound of the formula:

30




to provide a compound of the formula:



or its salt, in the above formulas,  
R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup>, A and E are each as defined above, and  
5 R<sup>6</sup> is aryl which may be substituted with suitable  
substituent(s); or pyridyl, or

3) reacting a compound of the formula:

10




or its salt with a compound of the formula:

15



or its reactive derivative at the carboxy or sulfo  
group, or a salt thereof to provide a compound of the  
20 formula:

20




25

or its salt, in the above formulas,  
R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, A, E and Q<sub>a</sub> are each as defined above,  
or

30 4) reacting a compound of the formula:


35



or its salt with a compound of the formula:




5 to provide a compound of the formula:




10 or its salt, in the above formulas,  
 $R^1$ ,  $R^3$ ,  $R^4$ ,  $R^6$ , A and E are each as defined above, or


5) reacting a compound of the formula:



or its salt with a compound of the formula:




or its reactive derivative at the carboxy or sulfo group, or a salt thereof to provide a compound of the formula:



30 or its salt, in the above formulas,  
 $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , A, E, X, Y and Q are each as defined above, or


6) reacting a compound of the formula:



or its reactive derivative at the carboxy or sulfo  
group, or a salt thereof with a compound of the  
formula:




or its salt to provide a compound of the formula:



or its salt, in the above formulas,  
 $\text{R}^1$ ,  $\text{R}^3$ ,  $\text{R}^4$ , A, E, X and  $\text{Q}_a$  are each as defined above,  
and

$\text{R}^7$  is lower alkyl, lower alkenyl, lower alkynyl,  
cyclo(lower)alkyl, aryl or a heterocyclic group,  
each of which may be substituted with suitable  
substituent(s), or


7) reacting a compound of the formula:



or its salt with a compound of the formula:



to provide a compound of the formula:



or its salt, in the above formulas,

$R^1$ ,  $R^3$ ,  $R^4$ , A and E are each as defined above,

$R_a^5$  is an N-protective group,


$R_a^2$  is lower alkyl, lower alkenyl, lower alkynyl,

5        cyclo(lower)alkyl, aryl or a heterocyclic group,  
       each of which may be substituted with suitable  
       substituent(s),


$Q_b$  is  $-\text{CH}_2-$ ,  $-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-$ ,  $-\text{SO}_2-$ , and

10         $Z_a$  is an acid residue, or

8)    subjecting a compound of the formula:




or its salt to elimination reaction of the N-protective  
 group to provide a compound of the formula:



or its salt, in the above formulas,

25         $R^1$ ,  $R_a^2$ ,  $R^3$ ,  $R^4$ , A, E and  $Q_b$ , are each as defined above,  
       or

9)    reacting a compound of the formula:




or its salt with a compound of the formula:

35



to provide a compound of the formula:



or its salt, in the above formulas,

$R^1$ ,  $R_a^2$ ,  $R^3$ ,  $R^4$ , A and E are each as defined above,

$Z_b$  is an acid residue,

$Q_C$  is  $\begin{array}{c} O \\ || \\ -C- \end{array}$ , and

$R_b^5$  is lower alkyl, or


10) reacting a compound of the formula:



or its salt with a compound of the formula:



to provide a compound of the formula:



or its salt, in the above formulas,

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , A, E and  $Q_a$  are each as defined above,

$Z_C$  is an acid residue, and

$Y_a$  is lower alkylene.

9. A pharmaceutical composition comprising a compound of claim 1, as an active ingredient, in association with a

pharmaceutically acceptable, substantially non-toxic carrier or excipient.

10. A compound of claim 1 for use as a medicament.
- 5
11. A method for therapeutic treatment and/or prevention of amnesia or dementia which comprises administering an effective amount of a compound of claim 1 to mammals.
- 10 12. Use of a compound of claim 1 for manufacture of a medicament for treating and/or preventing amnesia or dementia in mammals.

15

20

25

30

35